|Mr. Craig Alexander Collard||CEO & Director||N/A||N/A||1966|
|Ms. Ira Duarte||Executive VP & CFO||N/A||N/A||1969|
|Ms. Lisa Peraza||VP & Chief Accounting Officer||474.1k||N/A||1977|
|Dr. Thomas B. Ottoboni Ph.D.||Chief Scientific Officer and Senior VP of Pharmaceutical & Translational Sciences||N/A||N/A||1959|
|Mr. Ryan Craig||Vice President of Marketing||N/A||N/A||N/A|
|Mr. Sean T. Ristine||Senior Vice President of Human Resources||N/A||N/A||1970|
|Dr. Chris M. Storgard||Chief Medical Officer||N/A||N/A||1966|
|Mr. Robert Sullivan||Senior VP of Oncology Care Franchise & Commercial Operations||N/A||N/A||1978|
|Dr. William P. Forbes Pharm. D., Pharm.D.||Executive VP & Chief Development Officer||N/A||N/A||1962|
|Jeff Cohn||Executive Director, Assistant General Counsel & Assistant Secretary||N/A||N/A||N/A|
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
Heron Therapeutics, Inc.’s ISS governance QualityScore as of 1 November 2023 is 2. The pillar scores are Audit: 7; Board: 3; Shareholder rights: 1; Compensation: 5.